Fig. 7

GMCSF-MOG preferentially expanded Tregs from a memory T cell pool. On day − 1, a CD45.1-2D2-FIG mixed Treg and Tcon line (40% Tregs and 60% Tcons) was injected intravenously (1.25 × 10⁶ cells) into CD45.2 2D2-FIG-Rag1^−/− mice (n = 3). On day 0, 2D2-FIG-Rag1^−/− recipient mice were vaccinated with 4 nmol of GMCSF-MOG or 4 nmol GM-CSF + 4 nmol MOG^35–55. PBMCs were analyzed on day 4 for CD3, CD4, CD45.1, CD44, and FOXP3. Shown are analyses of donor CD45.1 CD3⁺ CD4⁺ T cells including a representative dot plots of GMCSF-MOG and “GM-CSF + MOG”-treated mice for CD44 (y-axis) and FOXP3 expression (x-axis) together with (b, d, f) cell numbers per microliter of blood and (c, e, g) percentages of designated cell populations. Statistical significance was analyzed by use of a two-tailed t test. (*p < 0.05, **p < 0.01, ***p < 0.001). Error bars represent SEM